FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
European Journal of Nuclear Medicine (Impact Factor: 5.38). 11/2009; 37(1):181-200. DOI: 10.1007/s00259-009-1297-4
Source: PubMed


The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about[18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) and is provided to help the physician and physicist to assist to carrying out,interpret, and document quantitative FDG PET/CT examinations,but will concentrate on the optimisation of diagnostic quality and quantitative information.

Download full-text


Available from: Thomas Beyer,
  • Source
    • "Recently, the combined guidelines from the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) were published for the use of 18F-FDG PET in inflammation and infection [42, 43]. Based on cumulated reported accuracies, more than 85% of these guidelines state that the major indications for the use of 18F-FDG PET/CT in infection and inflammation are sarcoidosis, peripheral bone osteomyelitis, spondylodiscitis, evaluation of fever of unknown origin, and the primary evaluation of vasculitis [44]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vascular prosthetic graft infection (VPGI) is a severe complication after vascular surgery. CT-scan is considered the diagnostic tool of choice in advanced VPGI. The incidence of a false-negative result using CT is relatively high, especially in the presence of low-grade infections. (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) scanning has been suggested as an alternative for the diagnosis and assessment of infectious processes. Hybrid (18)F-FDG PET/CT has established the role of (18)F-FDG PET for the assessment of suspected VPGI, providing accurate anatomic localization of the site of infection. However, there are no clear guidelines for the interpretation of the uptake patterns of (18)F-FDG as clinical tool for VPGI. Based on the available literature it is suggested that a linear, diffuse, and homogeneous uptake should not be regarded as an infection whereas focal or heterogeneous uptake with a projection over the vessel on CT is highly suggestive of infection. Nevertheless, (18)F-FDG PET and (18)F-FDG PET/CT can play an important role in the detection of VPGI and monitoring response to treatment. However an accurate uptake and pattern recognition is warranted and cut-off uptake values and patterns need to be standardized before considering the technique to be the new standard.
    BioMed Research International 08/2014; 2014:471971. DOI:10.1155/2014/471971 · 1.58 Impact Factor
  • Source
    • "A summary of imaging steps is provided in Table  2. PET imaging will be conducted according to EANM guidelines [17]. 18 F-FDG will be administered while the patient is supine on the PET-MRI table using MR compatible devices. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thermal ablation of colorectal liver metastases (CRLM) may result in local progression, which generally appear within a year of treatment. As the timely diagnosis of this progression allows potentially curative local treatment, an optimal follow-up imaging strategy is essential. PET-MRI is a one potential imaging modality, combining the advantages of PET and MRI. The aim of this study is evaluate fluorine-18 deoxyglucose positron emission tomography (FDG) PET-MRI as a modality for detection of local tumor progression during the first year following thermal ablation, as compared to the current standard, FDG PET-CT. The ability of FDG PET-MRI to detect new intrahepatic lesions, and the extent to which FDG PET-MRI alters clinical management, inter-observer variability and patient preference will also be included as secondary outcomes.
    BMC Medical Imaging 08/2014; 14(1):27. DOI:10.1186/1471-2342-14-27 · 1.31 Impact Factor
  • Source
    • "As there is no clear statement in the guidelines for the field of view (FOV) in FDG-PET/CT tumor imaging [1, 5–7], different practices are administered in different clinics. Huston et al. drew attention to this issue in their published article where they emphasized that there was a need for a standardized FOV [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The aim of this study was to detect additional findings in whole body FDG-PET/CT scan including the brain, calvarium, and scalp (compared to starting from the base of the skull) in cancer patients and to determine contributions of these results to tumor staging and treatment protocols. Materials and methods: We noted whether the findings related to the brain, calvarium, and scalp in 1359 patients had a potential to modify staging of the disease, chemotherapy protocol, radiotherapy protocol, and surgical management. We identified rates of metastatic findings on the brain, calvarium, and scalp according to the tumor types on FDG-PET/CT scanning. Results: We found FDG-PET/CT findings for malignancy above the base of the skull in 42 patients (3.1%), one of whom was a patient with an unknown primary tumor. Twenty-two of the metastatic findings were in the brain, 16 were in the calvarium, and two were in the scalp. Conclusion: This study has demonstrated that addition of the brain to the limited whole body FDG-PET/CT scanning may provide important contributions to the patient's clinical management especially in patients with lung cancer, bladder cancer, malignant melanoma, breast cancer, stomach cancer, and unknown primary tumor.
    BioMed Research International 06/2014; 2014:129683. DOI:10.1155/2014/129683 · 1.58 Impact Factor
Show more